BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The obesity therapeutics landscape is undergoing a radical exp
 ansion\, fueled by groundbreaking late-stage trials for Novo Nordisk's am
 ycretin and Metsera's exciting early data for its amylin-targeting shot. 
 Underscored by new insights into Eli Lilly's tirzepatide's cardiovascular
  benefits\, the field is witnessing a paradigm shift beyond GLP-1s to nov
 el mechanisms\, combination therapies\, and oral formulations. This new e
 ra of innovation promises wider accessibility and improved patient outcom
 es\, making the 2nd Innovation in Obesity Therapeutics Summit the essenti
 al forum for accelerating the next wave of treatment.\n\nThis year\, we'r
 e diving deep into game-changing potential of novel mechanisms of action\
 , muscle-preserving strategies\, and multi-agonist therapies. Hear from t
 he titans of the pharmaceutical industry\, including Novo Nordisk\, Eli L
 illy and Boehringer Ingelheim\, as well as innovative biotechs like Veru\
 , Supercede Therapeutics\, and Rivus Pharmaceuticals\, who will share the
 ir groundbreaking research and strategies. The pressure is on to continue
  work on developing best-in-class treatments that transform patient lives
 .\n\nDon't miss this pivotal opportunity to network with 60+ leading scie
 ntists and drug development experts in the field of obesity\, forge cruci
 al collaborations\, and be part of the solution. The future of obesity th
 erapeutics is being written now - be a part of it!\n\nURLs:Tickets: https
 ://go.evvnt.com/3203598-1?pid=185Brochure: https://go.evvnt.com/3203598-2
 ?pid=185\n\nTime: 9:00 AM - 5:00 PM\n\nVenue Details: DoubleTree by Hilto
 n Hotel San Diego - Mission Valley\, 7450 Hazard Center Drive\, San Diego
 \, California\, 92108\, United States\n\nCategory: Conferences | Science\
 , Health and Medicine | Pharmaceuticals\n\nPrices:Drug Developer Pricing 
 - Conference + Pre-Conference Focus Day: USD 4197.00\,Drug Developer Pric
 ing - Conference Only: USD 2999.00\,Academic Pricing - Conference + Pre-C
 onference Focus Day: USD 3597.00\,Academic Pricing - Conference Only: USD
  2599.00\,Service and Solution Pricing - Conference + Pre-Conference Focu
 s Day: USD 5097.00\,Service and Solution Pricing - Conference Only: USD 3
 699.00\n\nSpeakers: Anton Pekcec\, Director\, Cardiometabolic Diseases Re
 search\, Boehringer Ingelheim\, Julia Dunn\, Executive Director\, Medical
 \, Eli Lilly\, Martin Marro\, Executive Director\, Cell Pharmacology\, Ob
 esity and Complications\, Eli Lilly\, Sara Gry\, Vienberg Director\, Scie
 ntific Strategy\, Novo Nordisk\, Cory Schwartz\, Director\, Research and 
 Early Development\, iBio\, David Bearss\, President\, Chief Executive Off
 icer and Co-Founder\, Halia Therapeutics\, Gary Barnette\, Chief Scientif
 ic Officer\, Veru Inc.\, Gordon Foulkes\, Chief Executive Officer\, Lipid
 io Pharmaceuticals\, lan Zipkin\, Chief Executive Officer\, Supercede The
 rapeutics\, Inc.\, Jeremiah Bearss\, Chief Medical Officer\, Biolexis The
 rapeutics\, John Mayer\, Chief Scientific Officer\, Ambrosia Biosciences\
 , Laurent Audoly\, Chief Executive Officer\, Prive Bio\, Raj Reddy\, Chie
 f Executive Officer\, Canary Global\, Mitchell Steiner\, Chairman\, Chief
  Executive Officer and President\, Veru Inc\, Robert Schott\, Chief Medic
 al Officer\, Rivus Pharmaceuticals Inc.\, Tom Hardy\, Chief Medical Offic
 er\, Adipo Therapeutics\, David Tingley\, Founder\, Olio Labs\, Patrice L
 ee\, Head of R and D and Pharmacology\, Ambrosia Biosciences\, Marco Fala
 sca\, Professor Biochemistry\, Medicine and Surgery University of Parma\n
DTEND:20251204T170000
DTSTAMP:20260512T225914Z
DTSTART:20251202T090000
LOCATION:DoubleTree by Hilton Hotel San Diego - Mission Valley\, 7450\, Ha
 zard Center Drive\, San Diego\, California\, 92108\,
SEQUENCE:0
SUMMARY:The obesity therapeutics landscape is undergoing a radical expansi
 on\, fueled by groundbreaking late-stage trials for Novo Nordisk's amycre
 tin and M...
UID:970daa7c-a128-4455-81e2-52abcefef5c3
END:VEVENT
END:VCALENDAR
